Moderna, Inc. (MRNA)
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
- Ticker
- MRNA
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $86.97B
- 52-week range
- $22.28 - $280.80
Valuation
- Share price
- $215.27 (close of Nov 16, 2026)
- P/E (TTM)
- -30.45x
- Price to book
- 12.72x
- Price to free cash flow
- -44.15x
- Enterprise value
- $86.03B
- Book value per share
- $16.92
Price performance
| Period | Change |
|---|---|
| 1 day | -3.63% |
| 5 days | -19.97% |
| 1 month | -1.26% |
| 3 months | +239.97% |
| 6 months | +338.97% |
| Year to date | +629.98% |
| 1 year | +769.08% |
| 3 years | +181.21% |
| 5 years | -8.11% |
| All time | +1,057.37% |
Short interest
- As of
- Oct 30, 2026
- Short % of float
- 9.99%
- Shares short
- 33.19M
- Days to cover
- 1.76
- Change since prior report
- +1.80%
- Source
- FINRA consolidated short interest
Members of Congress who disclosed MRNA trades
Maria Elvira Salazar · Robert Bresnahan · Julie Johnson
Super investors holding MRNA
Ken Griffin (Citadel) · Ray Dalio (Bridgewater Associates)
Profitability and growth
- Return on equity
- -32.62%
- Return on invested capital
- -30.88%
- Return on assets
- -22.87%
- Return on capital employed
- -29.70%
- Gross margin
- 55.35%
- Net margin
- -145.16%
- EBITDA margin
- -147.27%
- Revenue growth
- -39.93%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- -2.27%
- Current ratio
- 3.62x
- Net debt to EBITDA
- 0.39x
Latest reported year
- Period end
- Dec 31, 2025
- Fiscal year
- 2025
- Revenue
- $1.94B
- Cost of revenue
- $868.00M
- Gross profit
- $1.08B
- EBITDA
- -$2.86B
- Net income
- -$2.82B
- Earnings per share
- $-7.26
- Research and development
- $3.13B
- Shares outstanding
- 389.00M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|---|---|---|---|
| 2025-12-31 | $1.94B | $1.08B | -$2.82B | -$7.26 |
| 2024-12-31 | $3.24B | $1.77B | -$3.56B | -$9.28 |
| 2023-12-31 | $6.85B | $2.15B | -$4.71B | -$12.33 |
| 2022-12-31 | $19.26B | $13.85B | $8.36B | $21.26 |
| 2021-12-31 | $18.47B | $15.85B | $12.20B | $30.31 |
| 2020-12-31 | $803.00M | $795.00M | -$747.00M | -$1.96 |
| 2019-12-31 | $60.21M | - | -$514.00M | -$1.55 |
| 2018-12-31 | $135.07M | - | -$384.73M | -$4.95 |
| 2017-12-31 | $205.82M | - | -$255.92M | -$4.18 |
| 2016-12-31 | $108.40M | - | -$216.21M | -$3.79 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|---|---|---|---|
| 2025-12-31 | 55.35% | -145.16% | -32.62% | -30.88% |
| 2024-12-31 | 54.76% | -110.04% | -32.67% | -33.47% |
| 2023-12-31 | 31.47% | -68.84% | -34.03% | -28.08% |
| 2022-12-31 | 71.88% | 43.41% | 43.73% | 40.38% |
| 2021-12-31 | 85.83% | 66.06% | 86.26% | 81.09% |
| 2020-12-31 | 99.00% | -93.03% | -29.17% | -27.27% |
| 2019-12-31 | - | -853.69% | -43.74% | -41.57% |
| 2018-12-31 | - | -284.84% | -25.15% | -25.22% |
| 2017-12-31 | - | -124.34% | - | - |
| 2016-12-31 | - | -199.46% | - | - |
Cash and debt by year
| Period end | Cash | Debt |
|---|---|---|
| 2025-12-31 | $5.80B | $590.00M |
| 2024-12-31 | $7.03B | - |
| 2023-12-31 | $8.60B | - |
| 2022-12-31 | $9.90B | - |
| 2021-12-31 | $10.73B | - |
| 2020-12-31 | $4.61B | - |
| 2019-12-31 | $1.10B | - |
| 2018-12-31 | $1.52B | - |
| 2017-12-31 | $756.03M | - |
| 2016-12-31 | $1.06B | - |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|---|---|
| 2025-12-31 | -$2.06B | $483.00M |
| 2024-12-31 | -$4.05B | $429.00M |
| 2023-12-31 | -$3.83B | $305.00M |
| 2022-12-31 | $4.58B | $226.00M |
| 2021-12-31 | $13.34B | $142.00M |
| 2020-12-31 | $1.96B | $93.00M |
| 2019-12-31 | -$491.00M | $81.00M |
| 2018-12-31 | -$436.63M | $72.56M |
| 2017-12-31 | -$389.88M | $40.05M |
| 2016-12-31 | $33.59M | $39.36M |
Investor relations
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-11-06 | Sep 2026 | -$1.10 |
| 2026-07-31 | Jun 2026 | -$1.97 |
| 2026-05-01 | Mar 2026 | -$3.02 |
| 2026-02-13 | Dec 2025 | -$2.60 |
| 2025-11-06 | Sep 2025 | -$2.15 |
| 2025-08-01 | Jun 2025 | -$2.99 |
| 2025-05-01 | Mar 2025 | -$2.92 |
| 2025-02-14 | Dec 2024 | -$2.69 |
Filings and sources
- Company website
- modernatx.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Incyte Corp (INCY) · Regeneron Pharmaceuticals, Inc. (REGN) · Insmed Inc (INSM) · Vertex Pharmaceuticals Inc (VRTX) · Bio-Techne Corp (TECH) · ICON plc (ICLR) · Eli Lilly & Co (LLY) · Charles River Laboratories International, Inc. (CRL)
Understanding these figures
Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades